NYSE:ABBVBiotechs
The Bull Case For AbbVie (ABBV) Could Change Following Its New AI-Driven US Manufacturing And CLL Win
In recent days, AbbVie announced a US$380 million plan to build two AI-enabled active pharmaceutical ingredient facilities in North Chicago and secured US FDA approval for an all-oral, fixed-duration VENCLEXTA plus acalabrutinib regimen for previously untreated chronic lymphocytic leukemia patients.
Together, these moves highlight AbbVie’s push to deepen its oncology footprint while scaling future neuroscience and obesity drug production within its US manufacturing base.
We’ll now examine...